Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TRX-248
- Development stage
- Unknown
- Lead developer
- Corsair Pharma
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Transdermal
01
Overview
TRX-248 is an **inactive prodrug of treprostinil** specifically developed for transdermal delivery via the proprietary TRX-248 Transdermal System patch. The patch, designed for once-daily application, delivers TRX-248 through the skin, where it enters the bloodstream and is rapidly converted in the liver to *treprostinil*. Treprostinil is a prostacyclin analog that mediates its effects by vasodilating pulmonary arteries, inhibiting platelet aggregation, and reducing smooth muscle cell proliferation. The transdermal TRX-248 system aims to deliver steady and continuous treprostinil blood levels, offering a noninvasive alternative to existing oral, inhaled, and parenteral formulations. Developed by Corsair Pharma, the product is primarily being investigated as a treatment for pulmonary arterial hypertension (PAH), with potential application in other forms of pulmonary hypertension[1][2][3][5][7][8].
- Brand names
- TRX-248 Transdermal SystemTRX248 Transdermal SystemTRX 248 Transdermal System
- Other names
- TRX-248 prodrugTRX248 prodrugTRX 248 prodrug
02
Targets
PTGER2 (Prostaglandin E2 receptor EP2)PTGDR (Prostanoid DP1 receptor)PTGIR (Prostanoid IP Receptor)
Beyond the preview
Go deeper on TRX-248.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TRX-248.